<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alpha Cognition Inc — News on 6ix</title>
<link>https://6ix.com/company/alpha-cognition-inc</link>
<description>Latest news and press releases for Alpha Cognition Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alpha-cognition-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835422978dffbe2df0e12a2.webp</url>
<title>Alpha Cognition Inc</title>
<link>https://6ix.com/company/alpha-cognition-inc</link>
</image>
<item>
<title>Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-may-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-may-14-2026</guid>
<pubDate>Tue, 28 Apr 2026 20:30:00 GMT</pubDate>
<description>VANCOUVER, B.C. & DALLAS, April 28, 2026--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close.</description>
</item>
<item>
<title>Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-to-participate-in-three-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-to-participate-in-three-upcoming-investor-conferences</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas, April 27, 2026--Alpha Cognition, Inc. (NASDAQ: ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May.</description>
</item>
<item>
<title>Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-strengthens-its-board-of-directors-with-appointment-of-bethany-sensenig</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-strengthens-its-board-of-directors-with-appointment-of-bethany-sensenig</guid>
<pubDate>Mon, 20 Apr 2026 21:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, April 20, 2026--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate str</description>
</item>
<item>
<title>Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a</description>
</item>
<item>
<title>Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-receives-issued-us-patent-for-alpha-1062-for-treatment-of-traumatic-brain-injury-6</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-receives-issued-us-patent-for-alpha-1062-for-treatment-of-traumatic-brain-injury-6</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a</description>
</item>
<item>
<title>Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-reports-fiscal-2025-financial-results-and-provides-operational-update</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-reports-fiscal-2025-financial-results-and-provides-operational-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million</description>
</item>
<item>
<title>Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-march-26-2026-608</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-march-26-2026-608</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)-- Alpha Cognition Inc.</description>
</item>
<item>
<title>Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-to-present-new-clinical-on-zunveylr-benzgalantamine-at-multiple-upcoming-alzheimers-association-international-conferences-20</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-to-present-new-clinical-on-zunveylr-benzgalantamine-at-multiple-upcoming-alzheimers-association-international-conferences-20</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a</description>
</item>
<item>
<title>Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-announces-first-patient-enrolled-in-beacon-real-world-effectiveness-study</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-announces-first-patient-enrolled-in-beacon-real-world-effectiveness-study</guid>
<pubDate>Wed, 25 Feb 2026 13:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.</description>
</item>
<item>
<title>Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-announces-issuance-additional-133000180</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-announces-issuance-additional-133000180</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas, February 18, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 12,551,491, entitled "Dosage Regimens for Benzgalantamine."</description>
</item>
<item>
<title>Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-provides-2026-corporate-213000795</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-provides-2026-corporate-213000795</guid>
<pubDate>Wed, 07 Jan 2026 21:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas, January 07, 2026--Alpha Cognition, Inc. (the "Company", "we", "us" and "ours") (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advancing treatments for cognitive and neuropsychiatric disorders, today announced a corporate update outlining strategic priorities for 2026 and summarizing key accomplishments achieved in 2025.</description>
</item>
<item>
<title>Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-participate-virtual-fireside-225100652</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-participate-virtual-fireside-225100652</guid>
<pubDate>Mon, 01 Dec 2025 22:51:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, December 01, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Alpha Cognition will participate in an upcoming virtual fireside chat hosted by Boris Peaker of Titan Partners. The discussion will focus on commercialization efforts and research initiatives to accelerate commercial adoption.</description>
</item>
<item>
<title>Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-reports-third-210000199</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-reports-third-210000199</guid>
<pubDate>Thu, 13 Nov 2025 21:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & GRAPEVINE, Texas, November 13, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the third quarter ended September 30, 2025, and provided an operational update.</description>
</item>
<item>
<title>Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-report-123000301</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-nasdaq-acog-report-123000301</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, October 30, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close.</description>
</item>
<item>
<title>Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-present-spartan-130000578</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-present-spartan-130000578</guid>
<pubDate>Wed, 15 Oct 2025 13:00:00 GMT</pubDate>
<description>Premier Event Showcases Innovative Growth Companies and Connects Them With Leading Institutional Investors NEW YORK, NY - October 15, 2025 (NEWMEDIAWIRE) - Alpha Cognition (NASDAQ: ACOG) today announced that it will present at the Spartan Capital Sec...</description>
</item>
<item>
<title>Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-present-clinical-data-203000965</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-present-clinical-data-203000965</guid>
<pubDate>Tue, 14 Oct 2025 20:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, October 14, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscienc</description>
</item>
<item>
<title>Alpha Cognition to Present Clinical Data at ASCP Annual Meeting</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-present-clinical-data-123000773</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-present-clinical-data-123000773</guid>
<pubDate>Mon, 06 Oct 2025 12:30:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, October 06, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.</description>
</item>
<item>
<title>Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-announces-pricing-031400715</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-announces-pricing-031400715</guid>
<pubDate>Wed, 01 Oct 2025 03:14:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, October 01, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, befor</description>
</item>
<item>
<title>Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-announces-proposed-205800901</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-announces-proposed-205800901</guid>
<pubDate>Tue, 30 Sep 2025 20:58:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, September 30, 2025--Alpha Cognition Inc. (Nasdaq: ACOG) (the "Company"), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwri</description>
</item>
<item>
<title>Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences</title>
<link>https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-nasdaq-acog-170000052</link>
<guid isPermaLink="true">https://6ix.com/company/alpha-cognition-inc/news/alpha-cognition-inc-nasdaq-acog-170000052</guid>
<pubDate>Thu, 28 Aug 2025 17:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia & DALLAS, August 28, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September.</description>
</item>
</channel>
</rss>